Endogena Therapeutics Completes Enrollment Ahead of Schedule in its Phase 1/2a Trial of EA-2353 for Retinitis Pigmentosa

Endogena Therapeutics Completes Enrollment Ahead of Schedule in its Phase 1/2a Trial of EA-2353 for Retinitis Pigmentosa

Related Keywords

United States ,San Francisco ,California ,Switzerland ,Toronto ,Ontario ,Canada ,Matthias Steger ,Infocus Clinical Research ,Endogena Therapeutics Inc ,Therapeutics Inc ,Endogena Therapeutics ,Infocus Clinical ,